Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Receivables for 5 consecutive years, with $2.1 million as the latest value for Q4 2024.

  • Quarterly Receivables rose 290.32% to $2.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2024, up 290.32% year-over-year, with the annual reading at $2.1 million for FY2024, 290.32% up from the prior year.
  • Receivables for Q4 2024 was $2.1 million at Fulcrum Therapeutics, up from $537000.0 in the prior quarter.
  • The five-year high for Receivables was $5.0 million in Q4 2021, with the low at $13000.0 in Q3 2022.
  • Average Receivables over 5 years is $1.4 million, with a median of $656000.0 recorded in 2023.
  • The sharpest move saw Receivables tumbled 95.42% in 2022, then surged 4361.54% in 2023.
  • Over 5 years, Receivables stood at $2.5 million in 2020, then soared by 97.55% to $5.0 million in 2021, then crashed by 95.42% to $229000.0 in 2022, then surged by 134.5% to $537000.0 in 2023, then soared by 290.32% to $2.1 million in 2024.
  • According to Business Quant data, Receivables over the past three periods came in at $2.1 million, $537000.0, and $580000.0 for Q4 2024, Q4 2023, and Q3 2023 respectively.